Investment analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a report released on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Price Performance
Shares of CYCC opened at $1.32 on Tuesday. The company has a 50-day simple moving average of $1.06 and a two-hundred day simple moving average of $1.58. The firm has a market capitalization of $2.84 million, a PE ratio of -0.08 and a beta of 0.51. Cyclacel Pharmaceuticals has a one year low of $0.75 and a one year high of $10.12.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same period in the previous year, the firm posted ($6.60) earnings per share. Analysts expect that Cyclacel Pharmaceuticals will post -2.29 EPS for the current fiscal year.
Institutional Investors Weigh In On Cyclacel Pharmaceuticals
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Featured Stories
- Five stocks we like better than Cyclacel Pharmaceuticals
- Ride Out The Recession With These Dividend KingsĀ
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Why is the Ex-Dividend Date Significant to Investors?
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.